Two pieces of good news are causing the share price to rise today. On the one hand, the risk of an indictment is decreasing and, in addition, there is Rumore, which $HIMS (+0,15%) will expand its new product categories on 15.09! 😍📈
I may buy back some of the shares I sold at the beginning of August! 💪
🚨 BIG NEWS FOR GLP-1 BLENDS
JUDGE COMMENTS ON THE "PERSONALIZATION" STANDARD
"Personalization doesn't mean that every compounded medicine has to be different for every patient; it just has to be tailored to the patient's specific goals."
The judge found that Willow Health met the "personalization" standard.
The judge also found that Lilly had not suffered sufficient commercial harm to justify the claim. Because Willow's GLP-1 blends were prescribed by physicians, Willow's ads did not directly deprive Lilly of sales.
‼️🚨 $HIMS CONFIRMS SEPT. 15 LAUNCH: NEW RX TESTOSTERONE DRUGS & HOME LAB 🚨‼️
- 5-month plan: $139/month & lab costs waived
- 10-month plan: $99/month & lab costs waived
- Home lab: $94 without order
(Plans = free home labs every 3 months)
Employee training began on 09/01.
